Table 5.

Comparison of North American with European Prospective Study

Variable	North American Study	European Study
Study Design	Prospective study of 175 subjects seen every 6 months for 5 years by 12 North American centers	Prospective study of 141 subjects evaluated every 6 months for 2 years by 15 European centers
Subjects	Probable MSA-P and MSA-C	Possible and probable MSA-P and MSA-C
Study Dates	Enrollment: Dec 2003 – May 2008. Last 60 month follow up May 2010	Jan 2003 to July 2004
Evaluated Variables	Defined minimal dataset and disease specific instruments (includes UMSARS I, II; COMPASS)	Same variables
Kaplan-Meier survival	Median 9.8 years; MSA-P=MSA-C from symptom onset to death	Median 9.8 years; MSA-P had shorter survival from baseline to death
K-M Predictors	Severe symptomatic autonomic failure at diagnosis associated with worse prognosis (by 2.4 years)	MSA-P has shorter survival than MSA-C from baseline to death
Rate of Progression	UMSARS I:	UMSARS I: yr 1, 6.5 (0.5/month); yr 2, 2.9 (0.2/month);
	Baseline to 12 months, 0.3/month	UMSARS II: yr 1, 8.2 (0.7/month); yr 2, 5.0 (0.4/month)
	12 to 24 months, 0.3/month
	UMSARS II:
	Baseline to 12 months, 0.5/month
	12 to 24 months, 0.3/month
Clinical Trial implications	Probable MSA represents late stage (plateau stage) with modest rate of change	Possible and early MSA is associated with greater rate of change
Autopsy Confirmation	16/16 (100%)	2/2 (100%)
Funding Source	NINDS (NS4 4233)	European Union; Oesterreichische Nationalbank and Austrian Science Fund